free porn
mobile porn
free porn
porn
porno izle

Agenda

Agenda

View the Agenda!

ARM’s Cell & Gene Therapy Investor Day is a full-day conference combining discussions between key opinion leaders, top analysts and senior executives in addition to presentations by the field’s most promising companies.

 

 

PROGRAM AGENDA

7:30 am REGISTRATION, BREAKFAST & NETWORKING
8:00 am WELCOME REMARKS
Speaker:
Robert Preti, Ph.D., Chairman, Alliance for Regenerative Medicine; President, PCT, a Caladrius company
8:10 am FIRESIDE CHAT: INNOVATION IN GENOME BASED MEDICINE
Moderator:
Olivier Danos, Ph.D., Chief Scientific Officer, REGENXBIO
Speaker:
James M. Wilson, M.D., Ph.D., Rose H. Weiss Professor and Director, Orphan Disease Center; Professor of Medicine and Pediatrics; Director, Gene Therapy Program, Perelman School of Medicine, University of Pennsylvania
8:55 am COMPANY PRESENTATIONS
The Great Room Harborside Room
8:55 am MiMedx Homology Medicines
9:10 am Celyad Orchard Therapeutics
9:25 am Fate Therapeutics AVROBIO
9:40 am BrainStorm Cell Therapeutics Capricor Therapeutics
9:55 am Audentes Therapeutics ReNeuron
10:10 am MORNING BREAK
10:25 am PANEL I: CELL THERAPY BEYOND ONCOLOGY: WHERE DOES THE GREATEST POTENTIAL LIE?
Moderator:
Edward Tenthoff, Managing Director and Senior Research Analyst, Piper Jaffray
Speakers:
Eduardo Bravo, CEO, TiGenix
Adam Gridley, President and CEO, Histogenics
Ralph Kern, M.D., Chief Medical Officer and Chief Operating Officer, BrainStorm Cell Therapeutics
Paul Laikind, Ph.D., President and CEO, ViaCyte
Emile Nuwaysir, Ph.D., CEO, BlueRock Therapeutics
11:10 am COMPANY PRESENTATIONS
The Great Room Harborside Room
11:10 am Mesoblast Lysogene
11:25 am BioCardia Precision Biosciences
11:40 am Kiadis Pharma Juventas Therapeutics
11:55 am Pluristem Therapeutics 4D Molecular Therapeutics
12:10 pm TiGenix Synpromics
12:25 pm LUNCH & NETWORKING
1:30 pm PANEL II: GENE THERAPY: COMMERCIALIZATION READINESS & MARKET ACCESS CHALLENGES
Moderator:
Joshua Schimmer, M.D., Managing Director and Senior Research Analyst, Piper Jaffray
Speakers:
Faraz Ali, Chief Business Officer, REGENXBIO
Mark Trusheim, Strategic Director, MIT Center for Biomedical Innovation’s New Drug Development Paradigms Initiative (NEWDIGS)
Arthur Tzianabos, Ph.D., President and CEO, Homology Medicines
Elizabeth White, Ph.D., Assistant VP, Early Commercial Planning, Rare Disease and Gene Therapy, Pfizer Innovative Health
2:15 pm COMPANY PRESENTATIONS
The Great Room Harborside Room
2:15 pm uniQure Histogenics
2:30 pm Sangamo Therapeutics Vericel
2:45 pm bluebird bio Bone Therapeutics
3:00 pm AFTERNOON BREAK
3:15 pm PANEL III: IMMUNO-ONCOLOGY: WHAT ARE THE KEY ISSUES AS FIRST PRODUCTS APPROACH COMMERCIALIZATION?
Moderator:
Timothy Schroeder, CEO, CTI Clinical Trial and Consulting
Speakers:
Usman Azam, M.D., President and CEO, Tmunity Therapeutics
David Epstein, Executive Partner, Flagship Pioneering
Rick Fair, President and CEO, Bellicum Pharmaceuticals
Jeffrey Walsh, Chief Financial and Strategy Officer, bluebird bio
4:00 pm COMPANY PRESENTATIONS
The Great Room Harborside Room
4:00 pm Abeona Therapeutics Universal Cells
4:15 pm Adverum Biotechnologies Fibrocell
4:30 pm AGTC Semma Therapeutics
4:45 pm GenSight Biologics Caladrius Biosciences
5:00 pm ViaCyte TxCell
5:15 pm NETWORKING RECEPTION
6:30 pm PROGRAM CLOSE